Prognostic factors in GBM patients are age, Karnofsky performance status (KPS), neurologic function status, extent of surgery, the methylation status of O6-methylguanine-DNA methyltransferase (MGMT), isocitrate dehydrogenase-1 (IDH-1) and IDH-2 status, and administration of EORTCH-NCIC protocol (5, 6). The gene discussed is MGMT; the disease is glioblastoma.